An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Inclusion Criteria: * Participant had agreed to provide their informed consent to participate per local requirements. * Participant had successfully completed Clinical Trial INS 1007-301 ASPEN, including the End of study Visit 12 prior to receiving treatment. * Requests for Post-Trial access for brensocatib had come from ASPEN investigator. * Had received brensocatib treatment. Exclusion Criteria: * Participant had experienced a serious adverse event deemed to be related to brensocatib during the study and required permanent participant is continuation. * The participant is immunocompromised or chronically treated with any investigational or commercialized immunomodulatory agent that is directed to any component of the adaptive or innate immune systems. Note: The use of any immunomodulatory agents (including but not limited to: bortezomib, ixazomib, thalidomide, cyclophosphamide, mycophenolate, Janus kinase inhibitors, IFN-γ, and azathioprine) is prohibited during the program. * The participant had undergone continuous use of high dose non-steroidal anti-inflammatory drugs. * The participant had undergone chronic use of systemic steroids for any chronic condition, except steroids with topical anti-inflammatory activities (ie, oral budesonide). * Participant had planned to receive live attenuated vaccines during the program (treatment must be postponed until 4 weeks after the last dose of drug). * Participant had planned to use investigational drugs.